secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scinai Immunotherapeutics Ltd. (SCNI)
CIK:        0001611747
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001213900-23-036435
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

BiondVax receives Nasdaq deficiency notice for minimum equity; deficit of $1.76M vs $2.5M required
--------------------------------------------------------------------------------

- Stockholders' deficit of $1.76M as of Dec 31, 2022, below Nasdaq's $2.5M minimum equity requirement.
- Company has until June 15, 2023 to submit a plan to regain compliance with Nasdaq Capital Market.
- If plan accepted, Nasdaq may grant up to 180-day extension; if rejected, company can appeal.
- No immediate effect on trading of ADSs under symbol BVXV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1611747/000121390023036435/0001213900-23-036435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1611747/000121390023036435/ea177985-8k_biondvax.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-036435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer